<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567642</url>
  </required_header>
  <id_info>
    <org_study_id>18-211</org_study_id>
    <nct_id>NCT03567642</nct_id>
  </id_info>
  <brief_title>A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers</brief_title>
  <official_title>Phase 1 Study of Combination Osimertinib, Platinum, Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers With Concurrent RB1 and TP53 Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of combining Osimertinib with either&#xD;
      Cisplatin or Carboplatin (at different dose levels) and Etoposide, to find out what effects,&#xD;
      if any, this combination of drugs has on people with EGFR mutant lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The MTD (maximum tolerated dose)</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the safety and toxicity profile of combination osimertinib, platinum (cisplatin or carboplatin), etoposide for patients with metastatic EGFR mutant lung cancers with concurrent RB1 and TP53 alterations.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initially, 6 patients will be enrolled and will begin treatment with osimertinib 80mg orally daily (3 who will be receiving cisplatin and 3 who will be receiving carboplatin). Cisplatin or carboplatin treatment will be decided by the treating physician prior to study registration. After 9 weeks (+/- 1 week)( 3 cycles) on osimertinib alone, carboplatin or cisplatin and etoposide will be added. Carboplatin is doses at an AUC of 5 or cisplatin at 60mg/m2 will be given on C4D1. Etoposide is dosed at 100mg/m2 given on Days 1-3 of C4. Only patients on osimertinib 80mg orally daily at the start of cycle 4 will be included in the 3+3 dose de-escalation portion of the study. Chemotherapy and osimertinib will be administered concurrently during cycles 4-7, and from cycle 8 onward, osimertinib monotherapy will be continued. Patients will present every 2 cycles post-chemo (Cycles 8, 10, 12, etc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Osimertinib 80mg daily</description>
    <arm_group_label>Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum</intervention_name>
    <description>Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4</description>
    <arm_group_label>Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 100mg/m2 or Etoposide 80mg/m2</description>
    <arm_group_label>Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Advanced biopsy-proven metastatic non-small cell lung cancer&#xD;
&#xD;
          -  Either have not started an EGFR TKI or may have started osimertinib within the last 9&#xD;
             weeks&#xD;
&#xD;
          -  Somatic activating mutation in EGFR in pre-treatment tumor biopsy or cfDNA&#xD;
&#xD;
          -  Evidence of a concurrent P53 alteration by IHC or NGS on pre-treatment tumor biopsy or&#xD;
             cfDNA&#xD;
&#xD;
          -  Evidence of a concurrent RB1 alteration by IHC or NGS on pre-treatment tumor biopsy or&#xD;
             cfDNA&#xD;
&#xD;
          -  Must have a site of disease amenable to repeat biopsy and be willing to undergo a&#xD;
             biopsy during treatment&#xD;
&#xD;
          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated&#xD;
&#xD;
          -  Karnofsky performance status (KPS) ≥ 70%&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Ability to swallow oral medication&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
               -  AST, ALT ≤ 3 x ULN&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5x ULN&#xD;
&#xD;
               -  Creatinine ≤ 1.5x ULN OR calculated creatinine clearance ≥ 60ml/min&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000 cells/mm^3&#xD;
&#xD;
               -  Hemoglobin≥8.0 g/dL&#xD;
&#xD;
               -  Platelets ≥100,000/mm^3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Started an EGFR TKI other than osimertinib or started osimertinib more than 9 weeks&#xD;
             ago&#xD;
&#xD;
          -  Any radiotherapy within 1 week of starting treatment on protocol.&#xD;
&#xD;
          -  Any major surgery within 1 weeks of starting treatment on protocol.&#xD;
&#xD;
          -  Any evidence of active clinically significant interstitial lung disease&#xD;
&#xD;
          -  Continue to have unresolved &gt; grade 1 toxicity from any previous treatment&#xD;
&#xD;
          -  Have pure small cell histology&#xD;
&#xD;
          -  Corrected QT interval using Fridericia's formula (QTcF)&gt;475msec or any clinically&#xD;
             significant (as deemed by the investigator) abnormalities in rhythm or conduction or&#xD;
             morphology of the resting EKG.&#xD;
&#xD;
          -  Patients are to be excluded from cisplatin treatment arm if they meet any of the&#xD;
             following criteria:&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  Hearing impairment requiring assistive device&#xD;
&#xD;
          -  Neuropathy&#xD;
&#xD;
          -  The treating provider does not feel as though the patient should receive cisplatin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Yu, MD</last_name>
    <phone>646-888-4274</phone>
    <email>yuh@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Kris, MD</last_name>
    <phone>646-888-4205</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
    <investigator>
      <last_name>Helena Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
    <contact_backup>
      <last_name>Mark Kris, MD</last_name>
      <phone>646-888-4205</phone>
    </contact_backup>
    <investigator>
      <last_name>Helena Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 13, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osimertinib</keyword>
  <keyword>Platinum</keyword>
  <keyword>Etoposide</keyword>
  <keyword>EGFR Mutant</keyword>
  <keyword>18-211</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

